Related Experiment Video
Updated: May 5, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
The Use of Patient-Reported Outcome Measures in Paediatric Haematopoietic Stem Cell Transplant: A Systematic Review
Rachel Penny1,2, Samantha Keogh2,3,4, Jill Shergold2
1Cancer and Palliative Care Outcomes Centre, Centre for Children's Health Research, Queensland University of Technology, Brisbane, QLD 4101, Australia.
Insights
Patient-Reported Outcome Measures (PROMs) are underused in pediatric Haematopoietic Stem Cell Transplantation (HSCT). Routine integration is needed to improve symptom management and patient care during HSCT.
Area of Science:
- Pediatric Hematology
- Oncology
- Nursing
- Health Services Research
Background:
- Children and adolescents undergoing Haematopoietic Stem Cell Transplantation (HSCT) experience significant, often under-reported symptoms.
- Patient-Reported Outcome Measures (PROMs) can capture patient experiences but their routine use in pediatric HSCT is unclear.
Purpose of the Study:
- To systematically review the use of PROMs in inpatient pediatric HSCT care.
- To examine the role of PROMs in symptom monitoring and clinical decision-making.
- To identify gaps for improving person-centered, developmentally appropriate care.
Main Methods:
- Systematic review of studies published 2014-2025 in major databases.
- Included studies on PROMs use during inpatient pediatric HSCT (0-18 years) up to Day +100.
- Narrative synthesis informed by Symptom Management Theory; Quality Assessment with Diverse Studies (QuADS) tool used.
Main Results:
- Seventeen studies described 20 PROMs for pediatric HSCT hospitalisation.
- PROMs captured physical/psychological symptoms (pain, nausea most frequent); improved detection/communication reported.
- Integration into routine clinical care was rare; limited evidence of PROMs-driven outcome improvements.
Conclusions:
- PROMs are not routinely integrated into clinical practice for pediatric HSCT.
- Current evidence offers a limited view of symptom trajectories and lived experiences.
- Systematic integration into workflows, EHRs, clinician training, and longitudinal research are needed.
Background/Objectives:
Children and adolescents undergoing Haematopoietic Stem Cell Transplantation (HSCT) experience complex symptoms, often under-reported by patients and undetected by clinicians, which cause distress. Patient-Reported Outcome Measures (PROMs) offer a way to capture symptom experiences directly from patients, with the potential of supporting effective symptom assessment and management, yet their routine use in paediatric HSCT remains unclear. This systematic review synthesises evidence on PROMs used during inpatient paediatric HSCT care, examining their role in symptom monitoring and clinical decision-making, and identifying gaps to strengthen person-centred, developmentally appropriate care.
Methods:
We searched the MEDLINE, CINAHL, Embase, APA PsychINFO, and Cochrane Library in October 2024 for studies published in English between 2014 and 2025 describing the use of PROMs during inpatient paediatric (0-18 years) HSCT admission (up to Day +100 post HSCT). In March 2025, prior to data extraction, we added additional studies published by authors of included studies. Two-stage independent screening and data extraction were conducted, and the Quality Assessment with Diverse Studies (QuADS) tool was used to appraise each study. Narrative syntheses informed by Symptom Management Theory were used to compare PROM use, clinical integration, and reported impacts.
Results:
Seventeen studies met inclusion criteria, describing 20 PROMs used during paediatric HSCT hospitalisation. PROMs captured a wide range of physical and psychological symptoms, with pain and nausea most frequently reported. While PROMs reportedly improve symptom detection and communication, integration into routine paediatric HSCT clinical care was rare; and only two studies systematically used PROMs data to guide symptom management. Evidence of PROMs-driven improvements in HSCT clinical outcomes was scarce, and longitudinal data on symptom trajectories were limited.
Conclusions:
PROMs are not routinely used to inform clinical practice in paediatric HSCT, and current evidence provides only a partial understanding of symptom trajectories and lived symptom experiences during the paediatric acute transplant admission. To realise the full potential of PROMs in enhancing symptom assessment and management, systematic PROMs integration into clinical workflows is required, supported by electronic health record integration, clinician training, and longitudinal research designs that capture symptom evolution across the transplant continuum.
More Related Videos
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Regulation of Hematopoietic Stem Cells
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion